These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients. Huang YS; Cheng CY; Sun HY; Cheng SH; Lu PL; Lee CH; Lee YT; Tsai HC; Yang CJ; Liu CE; Liou BH; Lin SP; Huang SH; Ho MW; Tang HJ; Hung CC; Microbiol Spectr; 2023 Jun; 11(3):e0512522. PubMed ID: 36988457 [TBL] [Abstract][Full Text] [Related]
4. Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study. Kovari H; Surial B; Tarr PE; Cavassini M; Calmy A; Schmid P; Bernasconi E; Rauch A; Wandeler G; Ledergerber B; HIV Med; 2021 Aug; 22(7):623-628. PubMed ID: 33880839 [TBL] [Abstract][Full Text] [Related]
5. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B. Nam H; Han JW; Lee SK; Yang H; Lee HL; Sung PS; Song MJ; Kwon JH; Jang JW; Chang UI; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK; Yang JM; Kim HY J Gastroenterol Hepatol; 2024 Aug; 39(8):1673-1683. PubMed ID: 38690711 [TBL] [Abstract][Full Text] [Related]
6. Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study. Abe K; Obara T; Kamio S; Kondo A; Imamura J; Goto T; Ito T; Sato H; Takahashi N AIDS Res Ther; 2021 Dec; 18(1):94. PubMed ID: 34876151 [TBL] [Abstract][Full Text] [Related]
7. Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting. Kauppinen KJ; Kivelä P; Sutinen J AIDS Patient Care STDS; 2019 Dec; 33(12):500-506. PubMed ID: 31742421 [TBL] [Abstract][Full Text] [Related]
8. Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service. Turner D; Drak D; O'Connor CC; Templeton DJ; Gracey DM AIDS Res Ther; 2019 Dec; 16(1):40. PubMed ID: 31810490 [TBL] [Abstract][Full Text] [Related]
9. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study. Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A; Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521 [TBL] [Abstract][Full Text] [Related]
10. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. Byun KS; Choi J; Kim JH; Lee YS; Lee HC; Kim YJ; Yoo BC; Kwon SY; Gwak GY; Lim YS Clin Gastroenterol Hepatol; 2022 Feb; 20(2):427-437.e5. PubMed ID: 33962041 [TBL] [Abstract][Full Text] [Related]
11. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. Suzuki K; Suda G; Yamamoto Y; Abiko S; Kinoshita K; Miyamoto S; Sugiura R; Kimura M; Maehara O; Yamada R; Kitagataya T; Shigesawa T; Ohara M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N PLoS One; 2022; 17(1):e0261760. PubMed ID: 35051189 [TBL] [Abstract][Full Text] [Related]
12. Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. Surial B; Ledergerber B; Calmy A; Cavassini M; Günthard HF; Kovari H; Stöckle M; Bernasconi E; Schmid P; Fux CA; Furrer H; Rauch A; Wandeler G; J Infect Dis; 2020 Jul; 222(4):637-645. PubMed ID: 32189003 [TBL] [Abstract][Full Text] [Related]
13. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: A retrospective observational study. Hikasa S; Shimabukuro S; Hideta K; Higasa S; Sawada A; Tokugawa T; Tanaka K; Yanai M; Kimura T J Infect Chemother; 2022 Mar; 28(3):396-400. PubMed ID: 34896027 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study. Farag MS; Fung S; Tam E; Doucette K; Wong A; Ramji A; Conway B; Cooper C; Tsoi K; Wong P; Sebastiani G; Brahmania M; Haylock-Jacobs S; Coffin CS; Hansen BE; Janssen HLA J Viral Hepat; 2021 Jun; 28(6):942-950. PubMed ID: 33749086 [TBL] [Abstract][Full Text] [Related]
15. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B. Cheng PN; Feng IC; Chen JJ; Kuo HT; Lee PL; Yu ML; Chiu YC; Chiu HC; Chien SC; Chen PJ; Liu CJ Aliment Pharmacol Ther; 2024 Jan; 59(2):230-238. PubMed ID: 37845815 [TBL] [Abstract][Full Text] [Related]
16. Estimated glomerular filtration rate slopes on tenofovir alafenamide. Ibrahim F; Campbell L; Bailey AC; Stockwell S; Waters L; Orkin C; Johnson M; Gompels M; De Burgh-Thomas A; Jones R; Schembri G; Mallon PW; Post FA HIV Med; 2020 Oct; 21(9):607-612. PubMed ID: 33021067 [TBL] [Abstract][Full Text] [Related]
17. Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice. Toyoda H; Leong J; Landis C; Atsukawa M; Watanabe T; Huang DQ; Liu J; Quek SXZ; Ishikawa T; Arai T; Yokohama K; Chuma M; Takaguchi K; Uojima H; Senoo T; Dang H; Maeda M; Hoang J; Le RH; Yasuda S; Thin KN; Tran S; Chien N; Henry L; Asai A; Fukunishi S; Cheung R; Lim SG; Trinh HN; Nguyen MH Hepatology; 2021 Aug; 74(2):656-666. PubMed ID: 33706421 [TBL] [Abstract][Full Text] [Related]
18. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation. Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597 [TBL] [Abstract][Full Text] [Related]
19. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ; J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595 [TBL] [Abstract][Full Text] [Related]
20. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. Plum PE; Maes N; Sauvage AS; Frippiat F; Meuris C; Uurlings F; Lecomte M; Léonard P; Paquot N; Fombellida K; Vaira D; Moutschen M; Darcis G BMC Infect Dis; 2021 Sep; 21(1):910. PubMed ID: 34488664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]